Fernando Civeira

List of Publications by Year
in descending order

154 papers	6,720 citations	109137 35 h-index	71532 76 g-index
171 all docs	171 docs citations	171 times ranked	6871 citing authors

#	Article	IF	Citations
1	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 331-340.	6.3	615
2	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	13.9	510
3	Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis, 2004, 173, 55-68.	0.4	425
4	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal, 2015, 36, ehv370.	1.0	395
5	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2019, 381, 531-542.	13.9	359
6	Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort. Circulation, 2015, 131, 2104-2113.	1.6	352
7	Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. Circulation, 2014, 129, 234-243.	1.6	204
8	Femoral and Carotid Subclinical Atherosclerosis Association With RiskÂFactors and Coronary Calcium. Journal of the American College of Cardiology, 2016, 67, 1263-1274.	1.2	172
9	A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32. American Journal of Human Genetics, 1999, 64, 1378-1387.	2.6	154
10	Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia. American Journal of Cardiology, 2008, 102, 1187-1193.e1.	0.7	153
11	Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome. Diabetes Care, 2019, 42, 303-310.	4.3	130
12	Higher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia. American Journal of Medicine, 2010, 123, 267-274.	0.6	102
13	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. Journal of Clinical Lipidology, 2018, 12, 920-927.e4.	0.6	97
14	Tendon Xanthomas in Familial Hypercholesterolemia Are Associated With Cardiovascular Risk Independently of the Low-Density Lipoprotein Receptor Gene Mutation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1960-1965.	1.1	95
15	A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. Journal of Medical Genetics, 2003, 40, 163-168.	1.5	83
16	Identification and validation of seven new loci showing differential DNA methylation related to serum lipid profile: an epigenome-wide approach. The REGICOR study. Human Molecular Genetics, 2016, 25, 4556-4565.	1.4	77
17	Frequency of Low-Density Lipoprotein Receptor Gene Mutations in Patients With a Clinical Diagnosis of Familial Combined Hyperlipidemia in a Clinical Setting. Journal of the American College of Cardiology, 2008, 52, 1546-1553.	1.2	73
18	The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2113-2121.	1.8	71

#	Article	IF	Citations
19	Aragon workersâ€™ health study â€“ design and cohort description. BMC Cardiovascular Disorders, 2012, 12, 45.	0.7	70
20	The Use of Achilles Tendon Sonography to Distinguish Familial Hypercholesterolemia from Other Genetic Dyslipidemias. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2203-2208.	1.1	69
21	IMPROVE-IT clinical implications. Should the â€œhigh-intensity cholesterol-lowering therapyâ€•strategy replace the â€œhigh-intensity statin therapyâ€?. Atherosclerosis, 2015, 240, 161-162.	0.4	64
22	Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. Atherosclerosis, 2012, 222, 449-455.	0.4	61
23	Homozygous Familial Hypercholesterolemia in Spain. Circulation: Cardiovascular Genetics, 2016, 9, 504-510.	5.1	61
24	Tendon xanthomas in familial hypercholesterolemia are associated with a differential inflammatory response of macrophages to oxidized LDL. FEBS Letters, 2005, 579, 4503-4512.	1.3	59
25	Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis, 2019, 284, 245-252.	0.4	55
26	Familial Hypercholesterolemia in Spain: Case-Finding Program, Clinical and Genetic Aspects. Seminars in Vascular Medicine, 2004, 4, 67-74.	2.1	53
27	The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations. The Application of Clinical Genetics, 2010, 3, 53.	1.4	49
28	Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis, 1996, 127, 273-282.	0.4	46
29	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis, 2002, 162, 245-251.	0.4	46
30	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. Journal of Molecular and Cellular Cardiology, 2017, 106, 55-67.	0.9	45
31	Simultaneous determination of oxysterols, phytosterols and cholesterol precursors by high performance liquid chromatography tandem mass spectrometry in human serum. Analytical Methods, 2013, 5, 2249.	1.3	44
32	Femoral Atherosclerosis In Heterozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 580-586.	1.1	43
33	Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis, 2010, 208, 437-441.	0.4	43
34	Functional Characterization and Classification of Frequent Low-Density Lipoprotein Receptor Variants. Human Mutation, 2015, 36, 129-141.	1.1	41
35	Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Scientific Reports, 2017, 7, 5596.	1.6	41
36	Common Genetic Variants Contribute to Primary Hypertriglyceridemia Without Differences Between Familial Combined Hyperlipidemia and Isolated Hypertriglyceridemia. Circulation: Cardiovascular Genetics, 2014, 7, 814-821.	5.1	36

#	Article	IF	Citations
37	Carotid Intima-Media Thickness in Subjects With No Cardiovascular Risk Factors. Revista Espanola De Cardiologia (English Ed), 2010, 63, 97-102.	0.4	35
38	Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 591-597.	1.1	35
39	Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136 â†' Ser) variant in multigenerational pedigree studies. Atherosclerosis, 1996, 122, 33-46.	0.4	34
40	STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. Journal of Hepatology, 2021, 74, 1429-1441.	1.8	34
41	Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?. Current Vascular Pharmacology, 2012, 10, 432-441.	0.8	34
42	Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis. International Journal of Cardiology, 2015, 201, 20-29.	0.8	33
43	ABCG5/G8 gene is associated with hypercholesterolemias without mutation in candidate genes and noncholesterol sterols. Journal of Clinical Lipidology, 2017, 11, 1432-1440.e4.	0.6	33
44	Mutation analysis in 36 unrelated Spanish subjects with familial hypercholesterolemia: Identification of 3 novel mutations in the LDL receptor gene. , 2000, 15, 483-484.		32
45	The apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis, 2002, 165, 127-135.	0.4	32
46	Increased Intestinal Cholesterol Absorption in Autosomal Dominant Hypercholesterolemia and No Mutations in the Low-Density Lipoprotein Receptor or Apolipoprotein B Genes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3667-3673.	1.8	32
47	The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture. Journal of Proteomics, 2014, 106, 61-73.	1.2	30
48	Effect of an alcohol-free beer enriched with isomaltulose and a resistant dextrin on insulin resistance in diabetic patients with overweight or obesity. Clinical Nutrition, 2020, 39, 475-483.	2.3	30
49	Identification of recurrent and novel mutations in the LDL receptor gene in Spanish patients with familial hypercholesterolemia. Human Mutation, 1998, 11, 413-413.	1.1	29
50	Serum ferritin is a major determinant of lipid phenotype in familial combined hyperlipidemia and familial hypertriglyceridemia. Metabolism: Clinical and Experimental, 2010, 59, 154-158.	1.5	29
51	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. Atherosclerosis, 2019, 287, 89-92.	0.4	29
52	Indicaciones de los inhibidores de PCSK9 en la prÃ¡ctica clÃnica. Recomendaciones de la Sociedad EspaÃ±ola de Arteriosclerosis (SEA), 2019. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 128-139.	0.4	28
53	Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. American Heart Journal, 1999, 138, 156-162.	1.2	26
54	Functional analysis of LDLR promoter and 5â€² UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Human Mutation, 2011, 32, 868-872.	1.1	26

#	Article	IF	Citations
55	The identification of five novel mutations in the lysosomal acid a-(1,4) glucosidase gene from patients with glycogen storage disease type II. , 1998, 11, 413-413.		25
56	A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22. Clinical Genetics, 2011, 79, 475-481.	1.0	25
57	Allelic polymorphism â^'491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. European Journal of Clinical Investigation, 2002, 32, 421-428.	1.7	24
58	Association of plasma markers of cholesterol homeostasis with metabolic syndrome components. A cross-sectional study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 651-657.	1.1	24
59	Energy-restricted, high-protein diets more effectively impact cardiometabolic profile in overweight and obese women than lower-protein diets. Clinical Nutrition, 2017, 36, 371-379.	2.3	24
60	Genetic predictors of weight loss in overweight and obese subjects. Scientific Reports, 2019, 9, 10770.	1.6	24
61	Effect of bergamot on lipid profile in humans: A systematic review. Critical Reviews in Food Science and Nutrition, 2020, 60, 3133-3143.	5.4	23
62	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. Atherosclerosis, 2017, 262, 107-112.	0.4	22
63	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. Atherosclerosis, 2019, 289, 162-172.	0.4	21
64	Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia. Atherosclerosis, 2020, 292, 143-151.	0.4	21
65	Sonographic evaluation of Achilles tendons and carotid atherosclerosis in familial hypercholesterolemia. Atherosclerosis, 2009, 204, 345-347.	0.4	20
66	Frequency of rare mutations and common genetic variations in severe hypertriglyceridemia in the general population of Spain. Lipids in Health and Disease, 2016, 15, 82.	1.2	20
67	How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment. Atherosclerosis Supplements, 2017, 26, 25-35.	1.2	20
68	Registro Nacional de Dislipemias de la Sociedad EspaÃ±ola de Arteriosclerosis: situaciÃ³n actual. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2017, 29, 248-253.	0.4	20
69	SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies. Biomedicines, 2021, 9, 612.	1.4	20
70	Analysis of apolipoprotein A-I, lecithin:cholesterol acyltransferase and glucocerebrosidase genes in hypoalphalipoproteinemia. Atherosclerosis, 2002, 163, 49-58.	0.4	19
71	Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia. American Heart Journal, 2003, 145, 999-1005.	1.2	19
72	Mutations inHFECausing Hemochromatosis Are Associated with Primary Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4391-4397.	1.8	19

#	Article	IF	Citations
73	Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis. Metabolism: Clinical and Experimental, 2011, 60, 830-834.	1.5	19
74	microRNA expression profile in human coronary smooth muscle cell-derived microparticles is a source of biomarkers. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2016, 28, 167-177.	0.4	19
75	High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study. Metabolism: Clinical and Experimental, 2020, 112, 154351.	1.5	19
76	An alcohol-free beer enriched with isomaltulose and a resistant dextrin modulates gut microbiome in subjects with type 2 diabetes mellitus and overweight or obesity: a pilot study. Food and Function, 2021, 12, 3635-3646.	2.1	19
77	An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 236-242.	1.1	18
78	Should We Forget About Low-Density Lipoprotein Cholesterol?. Journal of the American College of Cardiology, 2014, 63, 1228-1229.	1.2	18
79	Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients. American Journal of Cardiology, 2017, 119, 742-748.	0.7	17
80	Toxic Metals and Subclinical Atherosclerosis in Carotid, Femoral, and Coronary Vascular Territories: The Aragon Workers Health Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 87-99.	1.1	17
81	Serum Lipid Responses to Weight Loss Differ between Overweight Adults with Familial Hypercholesterolemia and Those with Familial Combined Hyperlipidemia. Journal of Nutrition, 2014, 144, 1219-1226.	1.3	16
82	Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids in Health and Disease, 2019, 18, 216.	1.2	16
83	Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. American Heart Journal, 2005, 150, 1154-1162.	1.2	15
84	Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. Metabolism: Clinical and Experimental, 2014, 63, 365-371.	1.5	15
85	Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes. Atherosclerosis, 2016, 246, 202-207.	0.4	15
86	Screening of APOB Gene Mutations in Subjects with Clinical Diagnosis of Familial Hypercholesterolemia. Human Biology, 2005, 77, 663-673.	0.4	14
87	A genetic variant in the LDLRpromoter is responsible for part of the LDL-cholesterol variability in primary hypercholesterolemia. BMC Medical Genomics, 2014, 7, 17.	0.7	14
88	Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia. Atherosclerosis, 2017, 263, 92-96.	0.4	14
89	Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight. Journal of Nutritional Biochemistry, 2018, 53, 48-57.	1.9	14
90	Age and sex influence the relationship between waist circumference and abdominal fat distribution measured by bioelectrical impedance. Nutrition Research, 2012, 32, 466-469.	1.3	13

#	Article	IF	Citations
91	Association of Ferritin Elevation and Metabolic Syndrome in Males. Results from the Aragon Workers' Health Study (AWHS). Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2081-2089.	1.8	13
92	Rare genetic variants with large effect on triglycerides in subjects with a clinical diagnosis of familial vs nonfamilial hypertriglyceridemia. Journal of Clinical Lipidology, 2016, 10, 790-797.	0.6	13
93	Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2020, 27, 1649-1660.	0.8	13
94	Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia. Journal of Inherited Metabolic Disease, 2007, 30, 970-977.	1.7	12
95	Bile acid synthesis precursors in familial combined hyperlipidemia: The oxysterols 24S-hydroxycholesterol and 27-hydroxycholesterol. Biochemical and Biophysical Research Communications, 2014, 446, 731-735.	1.0	12
96	Severe hypercholesterolemia and phytosterolemia with extensive xanthomas in primary biliary cirrhosis: Role of biliary excretion on sterol homeostasis. Journal of Clinical Lipidology, 2014, 8, 520-524.	0.6	12
97	Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE. Journal of Clinical Lipidology, 2016, 10, 1397-1405.e2.	0.6	12
98	Rapid resolution of xanthelasmas after treatment with alirocumab. Journal of Clinical Lipidology, 2016, 10, 1259-1261.	0.6	12
99	Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene. Atherosclerosis, 2019, 282, 143-147.	0.4	12
100	Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. Atherosclerosis, 2022, 349, 211-218.	0.4	12
101	Sleep duration and subclinical atherosclerosis: The Aragon Workers' Health Study. Atherosclerosis, 2018, 274, 35-40.	0.4	11
102	The island of Gran Canaria: A genetic isolate for familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 618-626.	0.6	11
103	Overexpression of the CXCL3 gene in response to oxidized low-density lipoprotein is associated with the presence of tendon xanthomas in familial hypercholesterolemia. Biochemistry and Cell Biology, 2009, 87, 493-498.	0.9	10
104	Variantes de un solo nucleÃ³tido asociadas con la hipercolesterolemia poligÃ©nica en familias diagnosticadas de hipercolesterolemia familiar. Revista Espanola De Cardiologia, 2018, 71, 351-356.	0.6	10
105	Different protein composition of low-calorie diet differently impacts adipokine profile irrespective of weight loss in overweight and obese women. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 133-142.	1.1	10
106	Association between non-cholesterol sterol concentrations and Achilles tendon thickness in patients with genetic familial hypercholesterolemia. Journal of Translational Medicine, 2018, 16, 6.	1.8	10
107	Lipid Profile Rather Than the LCAT Mutation Explains Renal Disease in Familial LCAT Deficiency. Journal of Clinical Medicine, 2019, 8, 1860.	1.0	10
108	Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy. Journal of Clinical Medicine, 2019, 8, 2209.	1.0	10

#	Article	IF	Citations
109	High-protein energy-restricted diets induce greater improvement in glucose homeostasis but not in adipokines comparing to standard-protein diets in early-onset diabetic adults with overweight or obesity. Clinical Nutrition, 2020, 39, 1354-1363.	2.3	10
110	MLb-LDLr. JACC Basic To Translational Science, 2021, 6, 815-827.	1.9	10
111	A double mutant [N543H+2393del9] allele in the LDL receptor gene in familial hypercholesterolemia: effect on plasma cholesterol levels and cardiovascular disease. Human Mutation, 2002, 20, 477-477.	1.1	9
112	Functional analysis of new 3â€² untranslated regions genetic variants in genes associated with genetic hypercholesterolemias. Journal of Clinical Lipidology, 2017, 11, 532-542.	0.6	9
113	Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1594-1603.	1.1	9
114	EstÃ¡ndares SEA 2019 para el control global del riesgo cardiovascular. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 1-43.	0.4	8
115	Haplotype analyses, mechanism and evolution of common double mutants in the human LDL receptor gene. Molecular Genetics and Genomics, 2010, 283, 565-574.	1.0	7
116	Eicosapentaenoic acid in serum phospholipids relates to a less atherogenic lipoprotein profile in subjects with familial hypercholesterolemia. Journal of Nutritional Biochemistry, 2013, 24, 1604-1608.	1.9	7
117	Effect of Lifestyle Intervention in the Concentration of Adipoquines and Branched Chain Amino Acids in Subjects with High Risk of Developing Type 2 Diabetes: Feel4Diabetes Study. Cells, 2020, 9, 693.	1.8	7
118	Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia. Atherosclerosis, 2021, 320, 47-52.	0.4	7
119	The fine line between familial and polygenic hypercholesterolemia. Clinical Lipidology, 2013, 8, 303-306.	0.4	6
120	Bile acid synthesis precursors in subjects with genetic hypercholesterolemia negative for LDLR/APOB/PCSK9/APOE mutations. Association with lipids and carotid atherosclerosis. Journal of Steroid Biochemistry and Molecular Biology, 2017, 169, 226-233.	1.2	6
121	Efficacy of repeated phlebotomies in hypertriglyceridemia and iron overload: A prospective, randomized, controlled trial. Journal of Clinical Lipidology, 2018, 12, 1190-1198.	0.6	6
122	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 128-139.	0.1	6
123	ANGPTL3 gene variants in subjects with familial combined hyperlipidemia. Scientific Reports, 2021, 11, 7002.	1.6	6
124	Iron deposits and dietary patterns in familial combined hyperlipidemia and familial hypertriglyceridemia. Journal of Physiology and Biochemistry, 2010, 66, 229-236.	1.3	5
125	New contributions to the study of common double mutants in the human LDL receptor gene. Die Naturwissenschaften, 2011, 98, 943-949.	0.6	5
126	Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia. Revista Espanola De Cardiologia (English Ed), 2017, 70, 551-558.	0.4	5

#	Article	IF	Citations
127	Disappearance of recurrent pancreatitis after splenectomy in familial chylomicronemia syndrome. Atherosclerosis, 2018, 275, 342-345.	0.4	5
128	Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia. Revista Espanola De Cardiologia (English Ed), 2021, 74, 664-673.	0.4	5
129	Rendimiento diagnÃ³stico de la secuenciaciÃ³n de genes de hipercolesterolemia familiar en sujetos con hipercolesterolemia primaria. Revista Espanola De Cardiologia, 2020, 74, 664-664.	0.6	5
130	Association of Cholesterol and Oxysterols in Adipose Tissue With Obesity and Metabolic Syndrome Traits. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3929-e3936.	1.8	5
131	Triglyceride Metabolism Modifies Lipoprotein(a) Plasma Concentration. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3594-e3602.	1.8	5
132	Tratamiento de la hipercolesterolemia familiar heterocigota en laÂinfancia y laÂadolescencia: unÂproblema noÂresuelto. Revista Espanola De Cardiologia, 2017, 70, 423-424.	0.6	4
133	EvaluaciÃ³n del coste-efectividad de la utilizaciÃ³n de los inhibidores de PCSK9. Endocrinologia, Diabetes Y NutriciÃ“n, 2021, 68, 369-371.	0.1	4
134	The leucine stretch length of PCSK9 signal peptide and its role in development of autosomal dominant hypercholesterolaemia: Unravelling the activities of P.LEU23DEL and P.LEU22_LEU23DUP variants. Atherosclerosis, 2017, 263, e37.	0.4	3
135	Single Nucleotide Variants Associated With Polygenic Hypercholesterolemia in Families Diagnosed Clinically With Familial Hypercholesterolemia. Revista Espanola De Cardiologia (English Ed), 2018, 71, 351-356.	0.4	3
136	Glycerol kinase deficiency in adults: Description of 4 novel cases, systematic review and development of a clinical diagnostic score. Atherosclerosis, 2020, 315, 24-32.	0.4	3
137	Effect of the Consumption of Alcohol-Free Beers with Different Carbohydrate Composition on Postprandial Metabolic Response. Nutrients, 2022, 14, 1046.	1.7	3
138	Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice. Journal of Clinical Lipidology, 2014, 8, 373-380.	0.6	2
139	Treatment of Heterozygous Familial Hypercholesterolemia in Children and Adolescents: An Unsolved Problem. Revista Espanola De Cardiologia (English Ed), 2017, 70, 423-424.	0.4	2
140	Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition. PLoS ONE, 2018, 13, e0204771.	1.1	2
141	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. JAMA Cardiology, 2020, 5, 1452.	3.0	2
142	Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Human Biology, 2005, 77, 663-73.	0.4	2
143	Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATVBAHA122315499.	1.1	2
144	Serum plant sterols as surrogate markers of dietary compliance inÂfamilial dyslipidemias. Clinical Nutrition, 2015, 34, 490-495.	2.3	1

#	Article	IF	Citations
145	Disbetalipoproteinemia y otras alteraciones relacionadas con la apolipoproteÃ¬na E. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 50-55.	0.4	1
146	Cost-effectiveness evaluation of the use of PCSK9 inhibitors. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2021, 68, 369-371.	0.1	1
147	LipoproteÃ¬nas clÃ¡sicas, terapÃ©uticas modernas. FarmacologÃa de las lipoproteÃ¬nas de alta densidad. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2006, 18, 10-19.	0.4	0
148	Hipercolesterolemia familiar en la infancia. El Ã©xito comienza aquÃ. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 179-180.	0.4	0
149	Familial hypercholesterolaemia in childhood: Success starts here. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 179-180.	0.1	0
150	Quantifying Thyroid Hormone Resistance in Obesity. Obesity Surgery, 2020, 30, 2411-2412.	1.1	0
151	Carga de enfermedad. CÃ¡lculo del riesgo cardiovascular y objetivos terapÃ©uticos. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 10-17.	0.4	0
152	Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins. Journal of Clinical Medicine, 2021, 10, 3494.	1.0	0
153	Genetic Factors of Cardiovascular Diseases. , 2008, , 44-55.		0
154	Monogenic Hypercholesterolemias. Contemporary Endocrinology, 2015, , 177-203.	0.3	0